Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 72INDUSTRY 34OTHER_GOV 2UNKNOWN 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 77Paclitaxel 48Trastuzumab 40Tamoxifen 39Doxorubicin 37Docetaxel 35Radiotherapy 32Fluorouracil 26Chemotherapy, Adjuvant 26Taxes 23Epirubicin 22Carboplatin 22Filgrastim 21Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 19Neoadjuvant Therapy 18aldesleukin 16Peripheral Blood Stem Cell Transplantation 16Bevacizumab 13Lapatinib 12CMF regimen 12Anastrozole 12exemestane 11Goserelin 11Capecitabine 11Biopsy 11veliparib 10sargramostim 10fludarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
799 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡